Home › Mercks Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
 

Keywords :   


Mercks Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early

2015-03-24 13:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYTRUDA Demonstrated Superior Overall Survival and Progression-Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the randomized, pivotal Phase 3 study (KEYNOTE-006) investigating KEYTRUDA (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the studys independent Data Monitoring Committee. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: will advanced met study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Nebraska celebrates new feedlot research, teaching, extension center
03.07Hurricane Beryl Public Advisory Number 20A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Eastern North Pacific Tropical Weather Outlook
03.07Atlantic Tropical Weather Outlook
03.07Genesus to restructure with Canada ZF Investments
03.07Global trade, domestic policy: What's at stake for pork industry
03.07Over 20,000 Tesco staff to split 30m from share schemes
More »